{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:58Z","timestamp":1790266318827,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013955","name":"Astellas Pharma BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100772","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:10:05Z","timestamp":1788520205000},"page":"100772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Extended cancer registry data for real-world evidence in bladder cancer: an update on the Prospective Bladder Cancer Infrastructure"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9639-3920","authenticated-orcid":false,"given":"F.M.","family":"Uunk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4409-4341","authenticated-orcid":false,"given":"J.","family":"Bosveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8839-8601","authenticated-orcid":false,"given":"A.G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-1326","authenticated-orcid":false,"given":"L.A.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7982","authenticated-orcid":false,"given":"R.P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.M.","family":"Suelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-1543","authenticated-orcid":false,"given":"A.","family":"Richters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-2147","authenticated-orcid":false,"given":"K.K.H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.H.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia van","family":"der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip J.M.","family":"Delaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilze E.W.","family":"van Onna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rikhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart P.","family":"Wijsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerkhofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan van den","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M.","family":"Leliveld-Kors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.A.","family":"Schout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-Jan","family":"Molijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc A.J.","family":"Roelofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn G.","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.N.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen L.","family":"Duizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm H.E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Baars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W.","family":"Postema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2026.100772_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2018.09.001","article-title":"To accelerate cancer prevention in Europe: challenges for cancer registries","volume":"104","author":"Zanetti","year":"2018","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmorw.2026.100772_bib2","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/0959-8049(95)00355-M","article-title":"Cancer incidence in the Netherlands in 1989 and 1990: first results of the nationwide Netherlands Cancer Registry","volume":"31","author":"van der Sanden","year":"1995","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100772_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047256","article-title":"Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the \u2018trials within cohorts\u2019 study ProBCI","volume":"11","author":"Richters","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100772_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12874-023-01941-5","article-title":"The Trial within Cohorts (TwiCs) study design in oncology: experience and methodological reflections","volume":"23","author":"Kessels","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmorw.2026.100772_bib21","series-title":"TNM classification of malignant tumours","article-title":"Rous","author":"Brierley","year":"2025"},{"key":"10.1016\/j.esmorw.2026.100772_bib22","series-title":"International classification of diseases for oncology (ICD-O-3.2)","year":"2019"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100772_bib5","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100772_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"M Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100772_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100772_bib8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100772_bib9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00434800","article-title":"The European Organization for Research and Treatment of Cancer approach to quality of life assessment: guidelines for developing questionnaire modules","volume":"2","author":"Sprangers","year":"1993","journal-title":"Qual Life Res"},{"issue":"14","key":"10.1016\/j.esmorw.2026.100772_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","article-title":"The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts","volume":"47","author":"van de Poll-Franse","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2026.100772_bib11","article-title":"Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: a population-based nationwide cohort study","volume":"46","author":"Richters","year":"2026","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100772_bib12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.euf.2021.08.009","article-title":"Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study","volume":"8","author":"Richters","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.esmorw.2026.100772_bib13","article-title":"Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer","volume":"11","author":"Bosveld","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.esmorw.2026.100772_bib14","article-title":"Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045","volume":"43","author":"Richters","year":"2025","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100772_bib15","doi-asserted-by":"crossref","first-page":"328.e17","DOI":"10.1016\/j.urolonc.2024.10.026","article-title":"Guidelines versus real-world data in metastatic bladder cancer: a population-based study on first-line chemotherapy treatment patterns","volume":"43","author":"Slotman","year":"2025","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100772_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s12885-020-07252-y","article-title":"Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study","volume":"20","author":"Schraa","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100772_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100772_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bju.16242","article-title":"Health-related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year","volume":"133","author":"Rogers","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100772_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12955-022-02064-z","article-title":"Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer","volume":"20","author":"Ripping","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.esmorw.2026.100772_bib20","article-title":"A cohort profile of the Graham Roberts study cohort","volume":"13","author":"Russell","year":"2023","journal-title":"Front Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:41:34Z","timestamp":1790264494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"alternative-id":["S2949820126000913"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100772","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended cancer registry data for real-world evidence in bladder cancer: an update on the Prospective Bladder Cancer Infrastructure","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100772"}}